Exagen Inc. (XGN) Q1 2026 Earnings Call Transcript
Exagen Q1 Earnings Call Highlights
Exagen Inc. (XGN) Reports Q1 Loss, Beats Revenue Estimates
Exagen Inc. Reports First Quarter 2026 Results
Zimmer Biomet (ZBH) Q1 Earnings and Revenues Top Estimates
Exagen Inc. to Announce First Quarter Financial Results on May 11, 2026
Exagen Inc. (NASDAQ:XGN) Given Average Recommendation of “Moderate Buy” by Analysts
Exagen Inc. (XGN) Q4 2025 Earnings Call Transcript
Exagen Inc. (XGN) Reports Q4 Loss, Beats Revenue Estimates
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results
Exagen Inc. (NASDAQ:XGN) Receives Average Rating of “Moderate Buy” from Analysts
Exagen Inc. to Participate in Upcoming Investor Conferences
Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026
Exagen Inc. Announces Select Preliminary 2025 Financial Results
Exagen Inc. (NASDAQ:XGN) Given Consensus Rating of “Moderate Buy” by Analysts
Exagen Inc. to Participate in Fourth Quarter Investor Conferences
Exagen Inc. (XGN) Q3 2025 Earnings Call Transcript
Exagen Inc. (XGN) Reports Q3 Loss, Tops Revenue Estimates
Exagen Inc. Reports Strong Q3 2025 Results
Exagen Inc. (NASDAQ:XGN) Receives Consensus Rating of “Moderate Buy” from Analysts
Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence
Exagen Inc. to Announce Third Quarter 2025 Financial Results on November 4, 2025
Exagen price target raised to $15 from $12 at KeyBanc
Exagen Inc. to Participate in Third Quarter Investor Conferences
Exagen Inc. (XGN) Q2 2025 Earnings Call Transcript
Exagen Q2 Revenue Jumps 14 Percent
Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates
Exagen Inc. Reports Strong Q2 2025 Results
Exagen (XGN) Soars 5.5%: Is Further Upside Left in the Stock?
Exagen Inc. Appoints Chas McKhann to Board of Directors
Exagen Inc. to Announce Second Quarter 2025 Financial Results on July 29, 2025
Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics
Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional Shares
Exagen Inc. Prices Public Offering of Common Stock
Exagen Inc. Announces Proposed Public Offering of Common Stock
Exagen Inc. (XGN) Q1 2025 Earnings Call Transcript
Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates
Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume
Exagen Inc. Announces Senior Secured Credit Facility with Perceptive Advisors
Exagen: Buy An Undervalued Diagnostics Developer That Is On The Path To Profitability
Exagen Inc. to Announce First Quarter 2025 Financial Results on May 5, 2025
Exagen Inc. (XGN) Q4 2024 Earnings Call Transcript
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights
Exagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025
Strength Seen in Exagen (XGN): Can Its 29.4% Jump Turn into More Strength?
Exagen Inc. to Participate in Upcoming Investor Conferences
Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results
Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD
Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform
Exagen, Inc. (XGN) Q3 2024 Earnings Call Transcript